RMRuben Muñiz

Ruben Muñiz

*This is an algorithmically generated author record based on publicly available information.

Ruben Muñiz has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 9 March 2026
      • p. 106093

    CHROME 2.0 Reduces Psychotropic Prescribing, Improving Neuropsychiatric Symptoms and Falls in People With Dementia.

    by Javier Olazarán, Luis Perea, Ana Rigueira, Jorge López-Álvarez, Ruben Muñiz

    The CHemical Restraints avOidance MEthodology (CHROME) was developed to help general physicians with quality prescribing of psychotropics for people with dementia (PwD). A new enhanced version (CHROME 2.0) was implemented and tested for improved outcomes. This was an observational, 13-month, prospective, 4-wave study. All residents with dementia at 10 Albertia nursing homes participated in the study. Neuropsychiatric syndromes and psychotropic prescriptions were first reviewed by physicians to comply with CHROME, and at the third and fourth waves, with CHROME 2.0, which included more stringent diagnostic criteria, implementation of environmental adaptations, and nonpharmacologic therapies. Medical data were extracted from the centralized information technology management software. A total of 673 residents were eligible, of whom 410 PwD (mean age ± SD, 87.2 ± 7.3 years; 78.3% female) completed the study. Frequency of ≥1 neuropsychiatric diagnosis was reduced from 76.7% to 36.1%, and frequency of ≥1 psychotropic prescribing was reduced from 84.1% to 39.8%. The highest relative reduction was observed for typical antipsychotics (93.2%), followed by other hypnotics (90.7%), short-intermediate benzodiazepines (86.4%), atypical antipsychotics (67.6%), long benzodiazepines (64.3%), and antidepressants (48.9%). Improvement was observed in all neuropsychiatric symptoms (d = 0.37), particularly hallucinations (69.5%), apathy (64.0%), depression (59.1%), delusions (59.0%), and appetite/eating symptoms (57.5%). Frequency of ≥1 fall diminished from 11.5% to 6.6% (P < .005). Monthly psychotropic costs per 100 PwD were reduced from €6.506 to €2.429. A significant decrease in psychotropic medication can be achieved concurrently with a marked improvement in both neuropsychiatric symptoms and falls. Psychotropic overprescription seems related to a culture of overestimating the capabilities of psychotropics while underestimating the potential of psychosocial interventions and the need for human contact of PwD. CHROME's limitation of psychotropics for severe cases contributed to shifting from a drug-centered care paradigm to a psychosocially more humane and integrative one that seems cost-effective and replicable, and should be further researched and implemented.

  • Quality of life (QoL) in community-dwelling and institutionalized Alzheimer's disease (AD) patients

    by Beatriz León-Salas, Javier Olazarán, Isabel Cruz-Orduña, Luis Agüera-Ortiz, José Luis Dobato, Meritxell Valentí-Soler, Ruben Muñiz, Ma Teresa González-Salvador, Pablo Martínez-Martín


  • Top Cited Papers
    Open Access

    Nonpharmacological Therapies in Alzheimer’s Disease: A Systematic Review of Efficacy

    by Javier Olazarán, Barry Reisberg, Linda Clare, Isabel Cruz, Jordi Peña-Casanova, Teodoro del Ser, Bob Woods, Cornelia Beck, Stefanie Auer, Claudia Lai, et al.

    Introduction: Nonpharmacological therapies (NPTs) can improve the quality of life (QoL) of people with Alzheimer’s disease (AD) and their carers. The objective of this study was to evaluate the best evidence on the effects of NPTs in AD and related disorders (ADRD) by performing a systematic review and meta-analysis of the entire field. Methods: Existing reviews and major electronic databases were searched for randomized controlled trials (RCTs). The deadline for study inclusion was September 15, 2008. Intervention categories and outcome domains were predefined by consensus. Two researchers working together detected 1,313 candidate studies of which 179 RCTs belonging to 26 intervention categories were selected. Cognitive deterioration had to be documented in all participants, and degenerative etiology (indicating dementia) had to be present or presumed in at least 80% of the subjects. Evidence tables, meta-analysis and summaries of results were elaborated by the first author and reviewed by author subgroups. Methods for rating level of evidence and grading practice recommendations were adapted from the Oxford Center for Evidence-Based Medicine. Results: Grade A treatment recommendation was achieved for institutionalization delay (multicomponent interventions for the caregiver, CG). Grade B recommendation was reached for the person with dementia (PWD) for: improvement in cognition (cognitive training, cognitive stimulation, multicomponent interventions for the PWD); activities of daily living (ADL) (ADL training, multicomponent interventions for the PWD); behavior (cognitive stimulation, multicomponent interventions for the PWD, behavioral interventions, professional CG training); mood (multicomponent interventions for the PWD); QoL (multicomponent interventions for PWD and CG) and restraint prevention (professional CG training); for the CG, grade B was also reached for: CG mood (CG education, CG support, multicomponent interventions for the CG); CG psychological well-being (cognitive stimulation, multicomponent interventions for the CG); CG QoL (multicomponent interventions for PWD and CG). Conclusion: NPTs emerge as a useful, versatile and potentially cost-effective approach to improve outcomes and QoL in ADRD for both the PWD and CG.